[{"id":"9eacdbab-1a64-457b-a4b2-200a00018493","acronym":"GPL study","url":"https://clinicaltrials.gov/study/NCT05335018","created_at":"2022-04-19T22:56:54.403Z","updated_at":"2025-02-25T12:38:12.292Z","phase":"Phase 2","brief_title":"GPL in Patients with Relapsed/refractory Diffuse Large B Cell Lymphoma","source_id_and_acronym":"NCT05335018 - GPL study","lead_sponsor":"Seoul National University Hospital","biomarkers":" BCL6","pipe":" | ","alterations":" CD20 expression","tags":["BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lenalidomide • Columvi (glofitamab-gxbm) • poseltinib (HM71224)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 76","initiation":"Initiation: 05/30/2022","start_date":" 05/30/2022","primary_txt":" Primary completion: 11/30/2025","primary_completion_date":" 11/30/2025","study_txt":" Completion: 11/30/2026","study_completion_date":" 11/30/2026","last_update_posted":"2024-12-16"}]